Metabolic pseudo-progression in a patient with metastatic KIT exon 11 GIST after one month of first-line imatinib: a case report

Author:

Tassinari Elisa1,Conci Nicole1,Battisti Giacomo2,Porta Francesco3,Scioscio Valerio Di3,Pirini Maria Giulia4,Nigro Maria Concetta1,Iezza Miriam1,Castagnetti Fausto1,Lovato Luigi3,Fanti Stefano2,Pantaleo Maria Abbondanza1,Margherita Nannini1

Affiliation:

1. Department of Medical and Surgical Sciences (DIMEC), University of Bologna, 40138, Bologna, Italy

2. Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna-Policlinico di Sant'Orsola, 40138 Bologna, Italy

3. Pediatric and Adult CardioThoracic and Vascular, Oncohematologic and Emergency Radiology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, via Giuseppe Massarenti, 9, 40138, Bologna, BO, Italy

4. Pathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna-Policlinico di Sant'Orsola, 40138 Bologna, Italy

Abstract

Abstract Background Positron emission tomography (PET) with 18-fluorodeoxyglucose (18FDG) has proven to be highly sensitive in early assessment of tumor response in GIST, especially in cases where there is doubt, or when early prediction of the response could be clinically useful for patient management. As widely known, kinase mutations have an undoubtful predictive value for sensitivity to imatinib and the inclusion of KIT and PDGFRa mutational analysis in the diagnostic work-up of all GIST is now considered as standard practice.Case presentation Herein we detailed described a case of an exon 11 KIT mutated-metastatic GIST patient, who presented an unexpected metabolic progression at the early 18FDG-PET evaluation after one month of first line imatinib, unconfirmed at the liver biopsy performed near after, which has conversely shown a complete pathological response.Conclusions This report aims to be aware of the existence of this metabolic pseudoprogression in GIST at the beginning of imatinib therapy, in order to avoid early treatment discontinuation. Therefore, an early metabolic progression during a molecular-targeted therapy always deserves to be evaluated in the context of the disease molecular profiling and in case of discordant finding between functional imaging and molecular background, a short-term longitudinal control should be suggested.

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3